Stage IIIC Cutaneous Melanoma AJCC v7 Suspended Phase 2 / 3 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Suspended2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02339571Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment